---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-25-000020"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:20:32.120103+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q2 net loss $18M; WTX-124 data on track for Q4 2025

## Summary
- Cash $77.6M as of June 30, 2025, providing runway into Q4 2026.
- Net loss $18.0M for Q2 2025 vs $17.2M in Q2 2024; R&D $13.1M, G&A $4.4M.
- WTX-124 Phase 1/1b interim data expected Q4 2025 in melanoma and renal cell carcinoma.
- Planning FDA engagement in H2 2025 to discuss registrational pathway for cutaneous melanoma.
- New candidate WTX-1011 (anti-STEAP1 T-cell engager) announced; additional candidate expected by year-end.

## SEC filing metadata
- accession: 0001785530-25-000020
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553025000020/0001785530-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553025000020/howl-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-25-000020
- JSON: https://secwatch.observer/filing/0001785530-25-000020.json
- Plain text: https://secwatch.observer/filing/0001785530-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.